UY34359A - ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?. - Google Patents

?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.

Info

Publication number
UY34359A
UY34359A UY0001034359A UY34359A UY34359A UY 34359 A UY34359 A UY 34359A UY 0001034359 A UY0001034359 A UY 0001034359A UY 34359 A UY34359 A UY 34359A UY 34359 A UY34359 A UY 34359A
Authority
UY
Uruguay
Prior art keywords
laquinimod
combination
multiple sclerosis
pharmaceutical composition
interferón
Prior art date
Application number
UY0001034359A
Other languages
English (en)
Inventor
Gilgun Yossi
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34359A publication Critical patent/UY34359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

El presente invento presenta un paquete y una composición farmacéutica compuesta por laquinimod e i nterferón-ß (IFN-ß) para el tratamiento de pacientes que tengan esclerosis múltiple (EM) o que pres enten un síndrome clínicamente aislado (SCA). Este invento también presenta una composición farmacé utica compuesta por una cantidad de laquinimod y una cantidad de IFN-ß. Este invento presenta tambi én una composición farmacéutica compuesta por laq uinimod para utilizarlo como terapia de adición o en combinación con interferón-ß, y una composició n farmacéutica compuesta por IFN-ß para utilizarlo como terapia de adición o en combinación con laq uinimod, para el tratamiento de pacientes con EM o que presenten un SCA.
UY0001034359A 2011-07-28 2012-10-01 ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?. UY34359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512817P 2011-07-28 2011-07-28
PCT/US2012/048689 WO2013016686A1 (en) 2011-07-28 2012-07-27 Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Publications (1)

Publication Number Publication Date
UY34359A true UY34359A (es) 2014-02-28

Family

ID=47597382

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034359A UY34359A (es) 2011-07-28 2012-10-01 ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.

Country Status (16)

Country Link
US (3) US20130028866A1 (es)
EP (1) EP2736336A4 (es)
JP (2) JP2014521659A (es)
KR (1) KR20140054129A (es)
CN (1) CN103781355A (es)
AU (2) AU2012286701A1 (es)
BR (1) BR112014002092A2 (es)
CA (1) CA2843432A1 (es)
EA (1) EA201490378A1 (es)
HK (1) HK1198278A1 (es)
MX (1) MX2014001048A (es)
SG (1) SG10201606204TA (es)
TW (1) TW201726137A (es)
UY (1) UY34359A (es)
WO (1) WO2013016686A1 (es)
ZA (1) ZA201401217B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
PE20130613A1 (es) * 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
PT2542079E (pt) 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
FR2988058B1 (fr) 2012-03-15 2014-10-03 A Fermetures As Dispositif de calage a quai de vehicule de transport de marchandises
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
AU2014216199A1 (en) * 2013-02-15 2015-09-03 Teva Pharmaceutical Industries Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
CA2917600A1 (en) * 2013-08-01 2015-02-05 Volker KNAPPERTZ Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
EP3303559A1 (en) * 2015-06-01 2018-04-11 Biogen MA Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
JP2009507003A (ja) * 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
AU2007258366B2 (en) * 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
EP2355660A4 (en) * 2008-10-13 2012-05-02 Biovista Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Also Published As

Publication number Publication date
EA201490378A1 (ru) 2014-07-30
KR20140054129A (ko) 2014-05-08
EP2736336A4 (en) 2015-03-04
AU2012286701A1 (en) 2014-03-06
MX2014001048A (es) 2014-07-09
US20160166648A1 (en) 2016-06-16
AU2016204909A1 (en) 2016-08-04
JP2017061482A (ja) 2017-03-30
CA2843432A1 (en) 2013-01-31
CN103781355A (zh) 2014-05-07
EP2736336A1 (en) 2014-06-04
WO2013016686A1 (en) 2013-01-31
HK1198278A1 (en) 2015-03-27
BR112014002092A2 (pt) 2017-02-21
NZ621215A (en) 2015-11-27
SG10201606204TA (en) 2016-09-29
ZA201401217B (en) 2015-08-26
JP2014521659A (ja) 2014-08-28
US20130028866A1 (en) 2013-01-31
TW201726137A (zh) 2017-08-01
US20150056281A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112013012587A2 (pt) composição farmacêutica para administração nasal
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2012158776A3 (en) Combination therapy for treatment of cancer
WO2013049280A3 (en) Sphingosine analogs, compositions, and methods related thereto
PH12020500472A1 (en) Autotaxin inhibitor compounds
BR112016006582A2 (pt) terapia combinada laquinimod para o tratamento da esclerose múltipla
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020